lifestyle.harcourthealth.com

Author: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2026
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 30, 2026
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

March 30, 2026
Vor Bio Announces $75 Million Private Placement with TCGX

March 27, 2026
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 23, 2026
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

February 23, 2026